Publication & Citation Trends
Publications
0 total
Abstract 7092: Highly potent and mutant-selective p53 Y220C reactivators with best-in-class potential
Cited by 0
Semantic Scholar
Glutamate-cysteine ligase catalytic subunit as a therapeutic target in acute myeloid leukemia and solid tumors.
Cited by 12
Semantic Scholar
Abstract 4197: Interaction of B lymphoma cells with the microenvironment affects ibrutinib sensitivity
Cited by 0
Semantic Scholar
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma OA
Cited by 54
Semantic Scholar
Abstract 4860: The BTK inhibitor ibrutinib modulates T cell immunity in mouse models and in differentiated human T cells
Cited by 1
Semantic Scholar
The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.
Cited by 3
Semantic Scholar
Ibrutinib Potentiated NK Cell-Mediated Cytotoxicity in Mouse Models of B-Cell Lymphomas
Cited by 3
Semantic Scholar
Abstract 3072: Combination of ibrutinib and corticosteroids in B-cell non-Hodgkin lymphomas (NHL)
Cited by 1
Semantic Scholar
Research Topics
Peptidase Inhibition and Analysis
(4)
Cell death mechanisms and regulation
(3)
RNA Interference and Gene Delivery
(3)
Ubiquitin and proteasome pathways
(3)
NF-κB Signaling Pathways
(3)
Affiliations
The University of Texas MD Anderson Cancer Center
Asia University
China Medical University
Rapt Therapeutics (United States)
University of Houston